drugset / Trial / NCT06801509

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

NCT06801509

Phase 1/2 Not yet recruiting 540 enrolled Sinocelltech Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.

Timeline

Start
2025-02-15
Primary completion
2025-11-10
Completion
2027-10-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ganwei Traditional medicine (herbal / TCM) 0.5 ml Subcutaneous
Subject SCTV04C Vaccine Intramuscular
Comparator VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine 50 ug Intramuscular

Indications